⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

Official Title: A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia

Study ID: NCT01883362

Study Description

Brief Summary: To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of California San Diego Moores Cancer Center, La Jolla, California, United States

University of California at Los Angeles Oncology, Los Angeles, California, United States

SCRI- Colorado Blood Cancer Institute, Denver, Colorado, United States

H Lee Moffitt Cancer Center and Research Institute Oncology, Tampa, Florida, United States

Northside Hospital, Atlanta, Georgia, United States

University of Chicago Medical Center, Chicago, Illinois, United States

Karmanos Cancer Institute Karmanos - Wayne State, Detroit, Michigan, United States

Mayo Clinic - Rochester, Rochester, Minnesota, United States

Washington University School Of Medicine-Siteman Cancer Ctr Washington U School of Med, Saint Louis, Missouri, United States

Hackensack University Medical Center Hackensack Univ Med Ctr (32), Hackensack, New Jersey, United States

University of North Carolina at Chapel Hill University of North Carolina 6, Chapel Hill, North Carolina, United States

University Hospitals Case Medical Center, Cleveland, Ohio, United States

Oregon Health Sciences University, Portland, Oregon, United States

Tennessee Oncology Sarah Cannon Research Inst., Nashville, Tennessee, United States

Vanderbilt Univeristy Oncology, Nashville, Tennessee, United States

Baylor Health Care System/Sammons Cancer Center Oncology, Dallas, Texas, United States

Texas Transplant Physicians Group Oncology 2, San Antonio, Texas, United States

Fred Hutchinson Cancer Research Center Oncology, Seattle, Washington, United States

Novartis Investigative Site, Toronto, Ontario, Canada

Contact Details

Name: Brian Elliott, MD

Affiliation: Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: